TW201922748A - 雙環碸及亞碸類以及其使用方法 - Google Patents

雙環碸及亞碸類以及其使用方法 Download PDF

Info

Publication number
TW201922748A
TW201922748A TW107138469A TW107138469A TW201922748A TW 201922748 A TW201922748 A TW 201922748A TW 107138469 A TW107138469 A TW 107138469A TW 107138469 A TW107138469 A TW 107138469A TW 201922748 A TW201922748 A TW 201922748A
Authority
TW
Taiwan
Prior art keywords
dihydro
pyrrolo
fluoro
triazole
phenyl
Prior art date
Application number
TW107138469A
Other languages
English (en)
Chinese (zh)
Inventor
史納黑爾 派托爾
葛羅葛瑞 漢米爾頓
克雷格 史迪瓦拉
慧芬 陳
布萊克 丹尼爾斯
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW201922748A publication Critical patent/TW201922748A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW107138469A 2017-10-31 2018-10-30 雙環碸及亞碸類以及其使用方法 TW201922748A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762579392P 2017-10-31 2017-10-31
US62/579,392 2017-10-31

Publications (1)

Publication Number Publication Date
TW201922748A true TW201922748A (zh) 2019-06-16

Family

ID=64051580

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107138469A TW201922748A (zh) 2017-10-31 2018-10-30 雙環碸及亞碸類以及其使用方法

Country Status (21)

Country Link
US (2) US11072617B2 (enExample)
EP (1) EP3704097B1 (enExample)
JP (1) JP2021501183A (enExample)
KR (1) KR20200083515A (enExample)
CN (1) CN111278809B (enExample)
AR (1) AR113811A1 (enExample)
AU (1) AU2018360270A1 (enExample)
BR (1) BR112020008446A2 (enExample)
CA (1) CA3078688A1 (enExample)
CL (1) CL2020001062A1 (enExample)
CO (1) CO2020003475A2 (enExample)
CR (1) CR20200168A (enExample)
IL (1) IL273847A (enExample)
MA (1) MA50503A (enExample)
MX (1) MX2020003451A (enExample)
PE (1) PE20211247A1 (enExample)
PH (1) PH12020550537A1 (enExample)
RU (1) RU2020115915A (enExample)
SG (1) SG11202002877RA (enExample)
TW (1) TW201922748A (enExample)
WO (1) WO2019086494A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110282A1 (es) 2016-12-02 2019-03-13 Hoffmann La Roche Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
CA3185865A1 (en) 2017-07-14 2019-01-17 F. Hoffmann-La Roche Ag Bicyclic ketone compounds and methods of use thereof
KR20200083515A (ko) 2017-10-31 2020-07-08 에프. 호프만-라 로슈 아게 2고리 설폰 및 설폭사이드, 및 이의 사용 방법
JP7585205B2 (ja) 2019-01-11 2024-11-18 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 二環式ピロロトリアゾールケトン化合物及びその使用方法
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ripk1抑制劑之異㗁唑啶及其用途
WO2023083847A1 (en) 2021-11-11 2023-05-19 Sanofi Isoxazolidines as ripk1 inhibitors and use thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) * 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3948903A (en) 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en) 1986-04-30 1986-06-04 Fbc Ltd Herbicides
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
DE69328430T2 (de) 1992-07-27 2001-01-25 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Zielgerichte liposome zur blut-hirne schranke
US6080772A (en) * 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
AU8071698A (en) 1997-06-13 1998-12-30 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
EP1254115A2 (en) 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
AU2003265585B2 (en) 2002-08-26 2008-07-03 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
CN101284136A (zh) 2002-12-03 2008-10-15 布朗歇特洛克菲勒神经科学研究所 传输物质穿过血脑屏障的人工低密度脂蛋白载体
CA2524269A1 (en) 2003-05-02 2004-11-18 Elan Pharmaceuticals, Inc. 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
EP2083009A1 (de) 2008-01-22 2009-07-29 Grünenthal GmbH Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN101824036A (zh) 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
KR20140096100A (ko) 2011-11-03 2014-08-04 에프. 호프만-라 로슈 아게 이환 피페라진 화합물
CA2871695A1 (en) 2012-05-22 2013-11-28 F. Hoffmann-La Roche Ag Substituted dipyridylamines and uses thereof
TWI498325B (zh) 2013-01-18 2015-09-01 Hoffmann La Roche 3-取代吡唑及其用途
TWI648274B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 (二)
CN105164114B (zh) 2013-05-01 2018-03-23 豪夫迈·罗氏有限公司 C‑连接的杂环烷基取代的嘧啶类和它们的用途
MA42164B1 (fr) 2013-05-01 2019-12-31 Hoffmann La Roche Composes biheteroaryle et leurs utilisations
RU2741810C2 (ru) 2013-07-10 2021-01-28 Вертекс Фармасьютикалз Инкорпорейтед Амиды конденсированного пиперидина в качестве модуляторов ионных каналов
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
PE20161223A1 (es) 2014-03-26 2016-11-12 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa)
EP3182974A1 (en) 2014-08-21 2017-06-28 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
CN107406462B (zh) 2015-03-09 2020-11-10 豪夫迈·罗氏有限公司 三环dlk抑制剂及其用途
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
SG10201913880XA (en) 2015-07-02 2020-03-30 Hoffmann La Roche Bicyclic lactams and methods of use thereof
US10751444B2 (en) 2015-08-07 2020-08-25 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
WO2017096301A1 (en) * 2015-12-04 2017-06-08 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1)
US10961258B2 (en) * 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN118994191A (zh) * 2016-02-05 2024-11-22 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
CN110267949A (zh) 2016-11-08 2019-09-20 塞科里昂医疗股份有限公司 sGC刺激剂
AR110282A1 (es) 2016-12-02 2019-03-13 Hoffmann La Roche Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
CA3185865A1 (en) 2017-07-14 2019-01-17 F. Hoffmann-La Roche Ag Bicyclic ketone compounds and methods of use thereof
WO2019072942A1 (en) 2017-10-11 2019-04-18 F. Hoffmann-La Roche Ag BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1
KR20200083515A (ko) 2017-10-31 2020-07-08 에프. 호프만-라 로슈 아게 2고리 설폰 및 설폭사이드, 및 이의 사용 방법

Also Published As

Publication number Publication date
AU2018360270A1 (en) 2020-03-26
PE20211247A1 (es) 2021-07-13
CN111278809B (zh) 2024-06-25
EP3704097A1 (en) 2020-09-09
KR20200083515A (ko) 2020-07-08
RU2020115915A (ru) 2021-12-01
US11072617B2 (en) 2021-07-27
BR112020008446A2 (pt) 2020-12-29
US20230002391A1 (en) 2023-01-05
EP3704097B1 (en) 2023-10-25
MX2020003451A (es) 2020-08-03
MA50503A (fr) 2020-09-09
JP2021501183A (ja) 2021-01-14
AR113811A1 (es) 2020-06-10
IL273847A (en) 2020-05-31
US20190127382A1 (en) 2019-05-02
SG11202002877RA (en) 2020-04-29
CL2020001062A1 (es) 2020-08-21
US12338241B2 (en) 2025-06-24
WO2019086494A1 (en) 2019-05-09
CO2020003475A2 (es) 2020-04-24
CN111278809A (zh) 2020-06-12
CA3078688A1 (en) 2019-05-09
PH12020550537A1 (en) 2021-03-22
CR20200168A (es) 2020-07-12
RU2020115915A3 (enExample) 2022-05-06
EP3704097C0 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
US11634436B2 (en) Pyridine lactam compounds and methods of use thereof
EP3526219B1 (en) Bicyclic pyridone lactams and methods of use thereof
TW201922748A (zh) 雙環碸及亞碸類以及其使用方法
US11071721B2 (en) Bicyclic amide compounds and methods of use thereof
US11673892B2 (en) Bicyclic compounds for use as RIP1 kinase inhibitors
TW201920149A (zh) 二環酮化合物及其使用方法
US20250282788A1 (en) Bicyclic ketone compounds and methods of use thereof
HK40062362A (en) Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
HK40062362B (en) Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
HK40024493B (zh) 二环碸类和亚碸类、以及其使用方法